Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Ovarian Neoplasms × Dalteparin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Venous Thromboembolism 16 Venous Thrombosis 12 Pulmonary Embolism 11 Neoplasms 10 Thrombosis 4 Thromboembolism 4 Pancreatic Neoplasms 4 Lung Neoplasms 4 Multiple Myeloma 3 Neoplasm Metastasis 2 Lymphoma 2 Hemorrhage 2 Colorectal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Uterine Cervical Neoplasms 1 Thrombophilia 1 Thrombocytopenia 1 Thrombocythemia, Essential 1 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Primary Myelofibrosis 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Precancerous Conditions 1 Ovarian Neoplasms 1 Obesity 1 Neoplasms, Plasma Cell 1

Interventions

Paclitaxel 326 Carboplatin 323 Bevacizumab 169 liposomal doxorubicin 104 Gemcitabine 103 pembrolizumab 98 olaparib 93 Cyclophosphamide 93 Topotecan 92 Cisplatin 92 niraparib 69 Docetaxel 57 Taxes 53 Doxorubicin 51 Drug Therapy 45 Filgrastim 39 fludarabine 38 Nivolumab 37 Magnetic Resonance Spectroscopy 34 Surveys and Questionnaires 33 Specimen Handling 33 Etoposide 32 Hyperthermic Intraperitoneal Chemotherapy 31 Blood Specimen Collection 28 Immunoglobulin G 27 Disulfides 27 Peripheral Blood Stem Cell Transplantation 26 Albumin-Bound Paclitaxel 25 durvalumab 24 aldesleukin 24

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00239980 2010-02-03

FOCUS

Ontario Clinical Oncology Group (OCOG)

Phase 2 Completed

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡